Zogenix, Inc. (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Zogenix, Inc. (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Zogenix, Inc. (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Zogenix, Inc. (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 27, 2016
52 pages — Published Sep 27, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Zogenix, Inc. (Zogenix) is a pharmaceutical company that develops and commercializes injectable therapies and delivery systems for treating central nervous system disorders and pain. The companys product portfolio includes Zohydro ER, Sumavel DosePro and undisclosed dosepro CNS product candidate. Its pipeline products include Relday and ZX008. Zogenixs Sumavel DosePro is a prefilled needle-free delivery system that treats people with acute migraine or cluster headaches. The company partners with Battelle to offer DosePro technology to its pharmaceutical partners. It also provides education materials on therapeutic products for patients and physicians.

Zogenix, Inc. (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed

  
Source:
Document ID
GDPH17626D
Country
Industry
Ticker
ZGNX=US
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Zogenix, Inc., Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201652
Zogenix, Inc., Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201671
Zogenix, Inc., Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201681
Zogenix, Inc., Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201691
Zogenix, Inc., Medical Devices Deals, 2010 to YTD 2016101
Zogenix, Inc., Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016112
Zogenix, Inc., Pharmaceuticals &Healthcare, Deal Details1336
  Venture Financing131
    Zogenix Secures US$15 Million In Venture Financing132
  Partnerships151
    Mallinckrodt Pharma And Zogenix Terminates Co-Promotion Agreement For Sumavel DosePro151
    Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro161
    Zogenix Enters Into Co-Promotion Agreement With Valeant Pharma For Migranal Nasal Spray172
    Zogenix And Battelle Memorial Institute Extend Co-Marketing Agreement For DosePro191
    Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro201
    Zogenix Enters Into Co-Marketing Agreement With Battelle Memorial Institute For DosePro212
    Zogenix Terminates Co-Promotion Agreement With Astellas Pharma US For Sumavel DosePro231
  Licensing Agreements241
    Zogenix Amends Licensing Agreement with Daravita241
    Zogenix Enters Into Licensing Agreement With Altus Formulation For Zohydro ER251
    Zogenix Amends Agreement with Elan Pharma261
    Zogenix Enters Into Licensing Agreement With DURECT272
  Equity Offering291
    Zogenix Raises USD98.3 Million in Public Offering of Shares292
    Zogenix Completes Public Offering Of Shares For US$69 Million312
    Zogenix Announces Public Offering Of Shares For Up To US$25 Million331
    Zogenix Completes Public Offering Of Units For US$70 Million342
    Zogenix Completes Public Offering Of Common Stock For US$61.4 Million362
    Zogenix Completes Private Placement Of Common Stock For US$1.5 Million381
    Zogenix Completes IPO For US$57.7 Million392
  Asset Transactions411
    Pernix Acquires Zohydro ER Business from Zogenix412
    Endo International Completes Acquisition of Sumavel DosePro Migraine Therapy Business from Zogenix432
    Cowen Healthcare Royalty Partners Acquires Royalties Of SUMAVEL DosePro And Zohydro From Zogenix452
  Acquisition471
    Zogenix Acquires Brabant Pharma for USD130 Million472
Zogenix, Inc. - Key Competitors491
Key Employees501
Locations And Subsidiaries511
  Head Office511
  Other Locations &Subsidiaries511
Appendix521
  Methodology521
  About GlobalData521
  Contact Us521
  Disclaimer521

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Zogenix, Inc. (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Zogenix-Inc-ZGNX-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-13952>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Zogenix, Inc. (ZGNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Zogenix-Inc-ZGNX-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-13952>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research